糖尿病性神経障害性疼痛市場- 世界の産業規模、シェア、動向、機会、予測、神経障害タイプ別、薬剤クラス別、流通チャネル別、地域別、競合別、2020-2030年

糖尿病性神経障害性疼痛の世界市場規模は2024年に16億4,000万米ドルに達し、2030年までのCAGRは5.68%で、予測期間中に目覚ましい成長を遂げると予測されています。

世界の糖尿病性神経障害性疼痛市場は、広範なヘルスケア産業の中でダイナミックかつ急速に発展している分野であり、世界の糖尿病有病率の増加を特徴としています。例えば、2022年、国際糖尿病連合は、20歳から79歳の成人の約5億3,700万人が糖尿病に罹患しており、世界の10人に1人が罹患していると報告しており、この疾患の世界の負担の増大が浮き彫りになっています。糖尿病性神経障害性疼痛は、糖尿病患者のかなりの割合が罹患している、糖尿病の苦痛で衰弱させる合併症です。この市場には、糖尿病性神経障害の患者が経験する慢性的な痛みや不快感を緩和することを目的とした、医薬品、医療機器、治療介入が幅広く含まれています。糖尿病性神経障害性疼痛世界市場の成長を促進する主な要因には、新興国を中心とした糖尿病罹患率の上昇、世界人口の高齢化などが挙げられます。糖尿病が増加し続けるにつれ、神経障害性疼痛につながることが多い糖尿病性神経障害の有病率も増加しています。そのため、効果的な疼痛管理ソリューションに対する需要が高まり、市場の技術革新が進んでいます。例えば、CDCによると、米国では人口の10.5％にあたる約3,420万人が糖尿病を患っており、これには診断済みのケースと未診断のケースの両方が含まれます。糖尿病と診断されていない、あるいは糖尿病予備軍も相当数に上り、糖尿病の管理と予防に対する関心が高まっていることが浮き彫りになっています。

市場促進要因

糖尿病の流行拡大

主な市場課題

治療抵抗性

主要市場動向

患者中心の医療

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の糖尿病性神経障害性疼痛市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 神経障害の種類別（末梢神経障害、自律神経障害、近位神経障害、局所神経障害）
  • 薬剤クラス別（抗うつ薬、抗けいれん薬、鎮痛薬）
  • 流通チャネル別（病院薬局、小売薬局、オンライン薬局）
  • 地域別
  • 企業別（2024）
• 市場マップ
  • 神経障害の種類別
  • 薬剤クラス別
  • 流通チャネル別
  • 地域別

第5章 アジア太平洋地域の糖尿病性神経障害性疼痛市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 神経障害の種類別
  • 薬剤クラス別
  • 流通チャネル別
  • 国別
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第6章 欧州の糖尿病性神経障害性疼痛市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第7章 北米の糖尿病性神経障害性疼痛市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第8章 南米の糖尿病性神経障害性疼痛市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカの糖尿病性神経障害性疼痛市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • エジプト

第10章 市場力学

• 促進要因
• 課題

第11章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第12章 世界の糖尿病性神経障害性疼痛市場：SWOT分析

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Eli Lilly and Company
• Grunenthal GmBH
• Collegium Pharmaceutical, Inc.
• Lupin Ltd
• Daiichi Sankyo Inc.
• Azurity Pharmaceuticals, Inc.
• Novartis AG
• Pfizer, Inc.
• Endo International plc.（Par Pharmaceutical）
• Johnson & Johnson

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Diabetic Neuropathic Pain Market was valued at USD 1.64 billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 5.68% through 2030. The Global Diabetic Neuropathic Pain Market is a dynamic and rapidly evolving sector within the broader healthcare industry, characterized by a growing prevalence of diabetes worldwide. For instance, in 2022, the International Diabetes Federation reported that approximately 537 million adults aged 20 to 79 had diabetes, affecting 1 in 10 individuals worldwide, highlighting the growing global burden of the disease. Diabetic neuropathic pain is a distressing and debilitating complication of diabetes mellitus, affecting a significant proportion of diabetic patients. This market encompasses a wide range of pharmaceuticals, medical devices, and therapeutic interventions aimed at alleviating the chronic pain and discomfort experienced by individuals with diabetic neuropathy.Key factors driving the growth of the Global Diabetic Neuropathic Pain Market include the escalating incidence of diabetes, particularly in emerging economies, as well as the aging global population. As diabetes continues to rise, so does the prevalence of diabetic neuropathy, which often leads to neuropathic pain. This, in turn, fuels the demand for effective pain management solutions and drives innovation in the market. For instance, according to the CDC, around 34.2 million people in the U.S., or 10.5% of the population, have diabetes, including both diagnosed and undiagnosed cases. A substantial number remain undiagnosed or have prediabetes, highlighting the growing concern of diabetes management and prevention.

Key Market Drivers

Escalating Diabetes Epidemic

The escalating diabetes epidemic is undeniably one of the most potent drivers behind the growth of the Global Diabetic Neuropathic Pain Market. Diabetes has reached pandemic proportions, affecting millions of individuals worldwide, and its prevalence continues to surge at an alarming rate.This unprecedented rise in diabetes cases translates directly into a larger pool of individuals at risk of developing diabetic neuropathy, a debilitating complication that frequently leads to neuropathic pain. According to the Ministry of Health and Family Welfare, in collaboration with the WHO Country Office for India and other partners, launched mDiabetes, a mobile health initiative to raise awareness about early diabetes diagnosis and treatment. Similarly, WHO and IDF are working globally to prevent and control diabetes. The WHO Diabetes Program focuses on preventing type 2 diabetes, minimizing complications, and enhancing the quality of life for individuals with diabetes, reinforcing global efforts to improve diabetes care and management.

Key Market Challenges

Treatment Resistance

One of the primary reasons behind treatment resistance is the heterogeneous nature of diabetic neuropathic pain. The condition varies in terms of severity, duration, and underlying mechanisms among individuals. As a result, what works effectively for one patient may not provide the same level of relief for another. This variability underscores the need for personalized treatment approaches tailored to the specific characteristics of each patient's neuropathic pain.

Another contributing factor to treatment resistance is the limited efficacy of current pharmaceutical therapies. While these medications can provide relief for some patients, a significant portion of individuals with diabetic neuropathic pain continues to experience chronic and often debilitating discomfort. This treatment gap highlights the urgent need for more effective and targeted treatment options that can address the multifaceted nature of neuropathic pain.

Key Market Trends

Patient-Centered Care

Patient-centered care is a pivotal trend that is significantly boosting the Global Diabetic Neuropathic Pain Market. In the past, healthcare decisions often followed a one-size-fits-all approach, but the recognition of the unique needs and preferences of individual patients has led to a paradigm shift in the management of diabetic neuropathic pain. This patient-centric approach places the patient at the center of their care, involving them actively in decision-making processes, and tailoring treatment strategies to meet their specific needs.

Key Market Players

Eli Lilly and Company

Grunenthal GmBH

Collegium Pharmaceutical, Inc.

Lupin Ltd

Daiichi Sankyo Inc.

Azurity Pharmaceuticals, Inc.

Novartis AG

Pfizer, Inc.

Endo International plc. (Par Pharmaceutical)

Johnson & Johnson

Report Scope:

In this report, the Global Diabetic Neuropathic Pain Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Diabetic Neuropathic Pain Market, By Neuropathy Type:

• Peripheral Neuropathy
• Autonomic Neuropathy
• Proximal Neuropathy
• Focal Neuropathy

Diabetic Neuropathic Pain Market, By Drug Class:

• Antidepressants
• Anticonvulsants
• Analgesics

Diabetic Neuropathic Pain Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Diabetic Neuropathic Pain Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Diabetic Neuropathic Pain Market.

Available Customizations:

Global Diabetic Neuropathic Pain Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Diabetic Neuropathic Pain Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Neuropathy Type (Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, Focal Neuropathy)
  • 4.2.2. By Drug Class (Antidepressants, Anticonvulsants, Analgesics)
  • 4.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 4.2.4. By Region
  • 4.2.5. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Neuropathy Type
  • 4.3.2. By Drug Class
  • 4.3.3. By Distribution Channel
  • 4.3.4. By Region

5. Asia Pacific Diabetic Neuropathic Pain Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Neuropathy Type
  • 5.2.2. By Drug Class
  • 5.2.3. By Distribution Channel
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Diabetic Neuropathic Pain Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Neuropathy Type
      • 5.3.1.2.2. By Drug Class
      • 5.3.1.2.3. By Distribution Channel
  • 5.3.2. India Diabetic Neuropathic Pain Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Neuropathy Type
      • 5.3.2.2.2. By Drug Class
      • 5.3.2.2.3. By Distribution Channel
  • 5.3.3. Australia Diabetic Neuropathic Pain Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Neuropathy Type
      • 5.3.3.2.2. By Drug Class
      • 5.3.3.2.3. By Distribution Channel
  • 5.3.4. Japan Diabetic Neuropathic Pain Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Neuropathy Type
      • 5.3.4.2.2. By Drug Class
      • 5.3.4.2.3. By Distribution Channel
  • 5.3.5. South Korea Diabetic Neuropathic Pain Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Neuropathy Type
      • 5.3.5.2.2. By Drug Class
      • 5.3.5.2.3. By Distribution Channel

6. Europe Diabetic Neuropathic Pain Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Neuropathy Type
  • 6.2.2. By Drug Class
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Diabetic Neuropathic Pain Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Neuropathy Type
      • 6.3.1.2.2. By Drug Class
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Germany Diabetic Neuropathic Pain Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Neuropathy Type
      • 6.3.2.2.2. By Drug Class
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Spain Diabetic Neuropathic Pain Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Neuropathy Type
      • 6.3.3.2.2. By Drug Class
      • 6.3.3.2.3. By Distribution Channel
  • 6.3.4. Italy Diabetic Neuropathic Pain Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Neuropathy Type
      • 6.3.4.2.2. By Drug Class
      • 6.3.4.2.3. By Distribution Channel
  • 6.3.5. United Kingdom Diabetic Neuropathic Pain Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Neuropathy Type
      • 6.3.5.2.2. By Drug Class
      • 6.3.5.2.3. By Distribution Channel

7. North America Diabetic Neuropathic Pain Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Neuropathy Type
  • 7.2.2. By Drug Class
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Diabetic Neuropathic Pain Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Neuropathy Type
      • 7.3.1.2.2. By Drug Class
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Mexico Diabetic Neuropathic Pain Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Neuropathy Type
      • 7.3.2.2.2. By Drug Class
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. Canada Diabetic Neuropathic Pain Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Neuropathy Type
      • 7.3.3.2.2. By Drug Class
      • 7.3.3.2.3. By Distribution Channel

8. South America Diabetic Neuropathic Pain Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Neuropathy Type
  • 8.2.2. By Drug Class
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Diabetic Neuropathic Pain Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Neuropathy Type
      • 8.3.1.2.2. By Drug Class
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. Argentina Diabetic Neuropathic Pain Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Neuropathy Type
      • 8.3.2.2.2. By Drug Class
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Colombia Diabetic Neuropathic Pain Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Neuropathy Type
      • 8.3.3.2.2. By Drug Class
      • 8.3.3.2.3. By Distribution Channel

9. Middle East and Africa Diabetic Neuropathic Pain Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Neuropathy Type
  • 9.2.2. By Drug Class
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Diabetic Neuropathic Pain Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Neuropathy Type
      • 9.3.1.2.2. By Drug Class
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Saudi Arabia Diabetic Neuropathic Pain Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Neuropathy Type
      • 9.3.2.2.2. By Drug Class
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. UAE Diabetic Neuropathic Pain Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Neuropathy Type
      • 9.3.3.2.2. By Drug Class
      • 9.3.3.2.3. By Distribution Channel
  • 9.3.4. Egypt Diabetic Neuropathic Pain Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Neuropathy Type
      • 9.3.4.2.2. By Drug Class
      • 9.3.4.2.3. By Distribution Channel

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Diabetic Neuropathic Pain Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Eli Lilly and Company
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (In case of listed)
  • 14.1.5. Recent Developments
  • 14.1.6. SWOT Analysis
• 14.2. Grunenthal GmBH
• 14.3. Collegium Pharmaceutical, Inc.
• 14.4. Lupin Ltd
• 14.5. Daiichi Sankyo Inc.
• 14.6. Azurity Pharmaceuticals, Inc.
• 14.7. Novartis AG
• 14.8. Pfizer, Inc.
• 14.9. Endo International plc. (Par Pharmaceutical)
• 14.10.Johnson & Johnson

15. Strategic Recommendations

16. About Us & Disclaimer